The stock of major pharmaceutical company Biocon is showing a weakness of 1.5% today.
Indeed, US drug regulator USFDA has released 6 comments in Form 483 for Biocon’s Bengaluru plant. USFD has given these comments after the pre-approval inspection of the company’s insulin drugmaking plant. The American drug regulator inspected the Biocon plant from February 25 to March 5. However, according to Biocon, the company is confident to address these shortcomings in a rapid way.
Explain that the company receiving the comments from USFDA has to reply in writing in 15 days with
On the other hand, the share of Biocon in BSE is open at Rs 609.80, down from Rs 625.45 in the previous closing price. At around 11 pm, it is running at Rs 615.90 with a weakness of Rs 9.55 or 1.53%. At this
Indian Stock Market- Get profitable Equity, MCX Service, HNI & Currency Services with good call accuracy. BSE Sensex & Nifty50. Our market researchers track the share positions and give best call accuracy to customers.